SOLUBILITY AND DISSOLUTION RATE ENHANCEMENT OF EZETIMIBE BY SOLID DISPERSION AND PELLETIZATION TECHNIQUES USING SOLUPLUS AS CARRIER
Objective: In the present investigation, an attempt was made to improve the surface characters and solubility of the drug by solid dispersion and coating it on the nonpareil sugar beads as pellets.
Methods: Ezetimibe solid dispersions were prepared by kneading method using soluplus. Crospovidone was added as a disintegrant in pellets. Ezetimibe pellets were prepared by dissolving soluplus and crospovidone in ethanol in different ratios and coated on nonpareil sugar beads as a drug layer by pan coating technique. Various physicochemical parameters like particle size, friability, angle of repose and drug content were evaluated for the prepared solid dispersions and pellet formulations. In vitro dissolution studies were carried out in 1% SLS using USP apparatus II. FTIR and SEM analysis were performed for solid dispersions, pellet formulations and its polymers to determine the interactions and surface characteristics.
Results: The physicochemical parameters were within the specified I. P limits. It was observed that the solid dispersion formulation ED5 showed better dissolution rate to the extent of 1.07 folds and 1.95 folds when compared to a marketed formulation and the pure drug, respectively. Similarly, pellet formulation EP5 containing 1:5 ratio of ezetimibe to soluplus showed an improved dissolution rate to the extent of 1.173 folds and 2.136 folds when compared to the marketed formulation and the pure drug, respectively. FTIR analysis revealed that there was no major interaction between the drug and the excipients.
Conclusion: From the present study, it was observed that the solubility of ezetimibe was enhanced by soluplus in pellet formulations when compared to solid dispersions.
2. Vial Bernasconi AC, Doelker E, Buri P. Prolonged release capsules divided and monolithic forms. STP Pharma Sci 1988;4:397-409.
3. Malinowski HJ, Smith WE. Effect of spheronization process variables on selected tablet properties. J Pharma Sci 1974;63:285-8.
4. Jackson IM, Roberts S, Timmins P, Sen H. Comparison of laboratory scale processing in the production of coated pellets. Pharm Tech Int 1989;1:29-32.
5. Gamlen MJ. Pellet manufacture for controlled release. Manuf Chem; 1985. p. 56-9.
6. Nastruzzi C, Cortesi R, Esposito E, Genovesi A, Spadoni A, Vecchio C, et al. Influence of formulation and process parameters on pellet production by powder layering technique. AAPS PharmSciTech 2000;12:E9.
7. Olsen K. Fluid bed equipment. In: Ghebre Sellassie I. (ed.) Pharmaceutical Pelletization Technology. Marcel and Dekker, New York; 1989. p. 39-69.
8. Bauer KH, Lehmann K, Osterwald HP, Rothgang G. Equipment for sugar coating and film coating processes coated pharmaceutical dosage forms. Medpharm Scientiphic Publishers, Stuttgart; 1998.
9. Felton LA. Film coating of oral solid dosage form. In: Swarbrick J. (ed.) Encyclopedia of Pharmaceutical Technology. Informa Healthcare 2007;3:1729–47.
10. DiPiro JT, Talbert RL, Yee GC, Marzke GR, Wells BG, Posey LM. editors. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York: The McGraw-Hill Companies, Inc; 2008.
11. Garcia Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP. The target of ezetimibe is niemann-pick C1-like 1 (NPC1L1). Proc Natl Acad Sci USA 2005;102:8132-7.
12. Tirumalesh N, Chowdary KPR. Enhancement of dissolution rate of telmisartan by solid dispersion in starch 1500 and soluplus alone and in combination. Ind Am J Pharm Sci 2017;48:2274-9.
13. Mendhe AA, Kharwade RS, Mahajan UN. Dissolution enhancement of poorly water-soluble drug by cyclodextrins inclusion complexation. Int J Appl Pharm 2016;84:60-5.
14. Kausalya J, Suresh K, Padmapriya S, Anusha R, Senthilnathan B. Solubility and dissolution enhancement of Telmisartan using various techniques. Int J Pharm Tech Res 2011;33:1737–49.
15. Ashwini K, Santosh S, Vivek R, Yogesh K, Ashish J. Review on antihyperlipidemic lipophilic drugs and their novel formulation approaches. Int J Pharm Pharm Sci 2017;99:1-8.
16. Gordon RE, Rosanske TW, Fonner DE, Anderson NR, Banker GS. Granulation technology and tablet characterization. Pharmaceutical dosage forms: tablets. 1990;2:324.
17. Train D. Some aspects of the property of angle of repose of powders. J Pharm Pharmacol 1958:1;10(S1).
18. Vidyadhara S, Sasidhar RL, Sivaprasad S, Vikas S, Harika D. Dissolution rate enhancement of Irbesartan and development of fast dissolving tablets. Egypt Pharm J 2016;15:150–7.
19. Tungikar AV, Mahale NB, Rode RB. Design and characterization of solubility enhancement of Ezetimibe–a poorly water-soluble drug. World J Pharm Pharm Sci 2014;42:215-28.
20. Sandeep KV, Roop NG, Kalaiselvan R, Romi S. Design and statistical evaluation of a multiunit delivery system containing nisoldipine-soluplus® solid dispersion for hypertension chronotherapy. Int J Pharm Pharm Sci 2016;810:170-7.
21. Sanjeevani D, John D, Kiran M, Hoshmani A. Solubility enhancement of ritonavir by hot melt extrusion. Int J Pharm Pharm Sci 2016;8:309-12.
This work is licensed under a Creative Commons Attribution 4.0 International License.